Action BIONTECH SE
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Communiqués BioNTech SE Xetra

Actions

US09075V1026

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union  
GL
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
GL
Africa Should Aim for New Vaccines, Therapeutics - Kagame
AQ
BioNTech : INFORMATION INCLUDED AS PART OF THIS FORM 6 K Form 6 K
PU
BioNTech : ASCO 2024
PU
BioNTech : ASCO 2024
PU
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
AQ
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
GL
Patents, Policies And Privacy: The Highs And Lows Of Technology In IP
AQ
Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns
AQ
BioNTech : Publication of the resolutions and system for the remuneration of Supervisory Board Members (resolution of the AGM on 17 May 2024)
PU
BioNTech : Publication of the resolutions and system for the remuneration of Supervisory Board Members (resolution of the AGM on 1 June 2022)
PU
BioNTech : Publication of the resolutions and system for the remuneration of Supervisory Board Members (resolution of the AGM on 22 June 2021)
PU
BioNTech : Publication of the resolutions and system for the remuneration of the members of the management Board (resolution of the AGM on 17 May 2024)
PU
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
GL
MediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech, expanding their global strategic partnership
PR
BioNTech : to Evaluate NanoTag’s Target Labeling System in Different Therapeutic Areas
PU
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
GL
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
GL
BioNTech : Corporate Presentation
PU
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action BNTX
  4. Action
  5. Actualités BioNTech SE
  6. Communiqués